PRESS RELEASE

Closing completed: Kühne Holding is new majority shareholder of pharma contract manufacturer Aenova

- **After a successful regulatory approvals process, the takeover of the pharma contract development and manufacturing organization Aenova by Kühne Holding AG was closed on August 29, 2024.**
- **The previous owner, the private investment company BC Partners, will support Aenova alongside Kühne Holding AG as a minority shareholder.**

Starnberg, 30 August 2024 - Aenova is one of the world's leading CDMOs (Contract Development and Manufacturing Organizations) in the pharmaceutical and healthcare industry. Headquartered in Starnberg near Munich and with around 4,000 employees at 14 production sites worldwide, the company is a full-service provider for the development, manufacturing, and packaging of drug products for pharma companies around the globe.

At the end of April 2024, it was announced that Kühne Holding AG has entered into a definitive agreement to acquire Aenova from leading international investment firm BC Partners. The regulatory approvals process has been conducted over the past few months. The closing took place on August 29, 2024.

"With Kühne Holding AG, we have a strong partner for the further implementation of our strategy to make Aenova the leading CDMO with flexible capacities and innovative specialty platforms. We will continue to strengthen our competitive advantage in the production of conventional dosage forms while expanding in-demand technology platforms and development services to meet the future needs of our customers and thus provide patients worldwide with our services," explains **Jan Kengelbach, who has led Aenova as CEO since 2018.**

Development, production and packaging of highly effective drugs (Photo: Aenova)

Semi-continuous production of high-volume conventional solids (Photo: Aenova)

-Ends-

About the Aenova Group

The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full-service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to food supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dosage, OEB 1 to 5 (Occupational Exposure Band). Around 4,000 employees at 14 locations in Europe and the USA contribute to the company's success. Further information can be found at www.aenova-group.com.

Press contact

Dr. Susanne Knabe
Head of Corporate Communication & PR
Aenova Holding GmbH
Berger Straße 8 - 10
D-82319 Starnberg

Mobile: +49 170 22 368 42
E-mail: susanne.knabe@aenova-group.com